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ABSTRACT
The existing cross-validated risk scores (CVRS) design has been proposed for developing and testing
the efficacy of a treatment in a high-efficacy patient group (the sensitive group) using high-dimensional
data (such as genetic data). The design is based on computing a risk score for each patient and dividing
them into clusters using a non-parametric clustering procedure. In some settings it is desirable to
consider the trade-off between two outcomes, such as efficacy and toxicity, or cost and effectiveness.
With this motivation, we extend the CVRS design (CVRS2) to consider two outcomes. The design
employs bivariate risk scores that are divided into clusters. We assess the properties of the CVRS2
using simulated data and illustrate its application on a randomised psychiatry trial. We show that
CVRS2 is able to reliably identify the sensitive group (the group for which the new treatment provides
benefit on both outcomes) in the simulated data. We apply the CVRS2 design to a psychology clinical
trial that had offender status and substance use status as two outcomes and collected a large number
of baseline covariates. The CVRS2 design yields a significant treatment effect for both outcomes,
while the CVRS approach identified a significant effect for the offender status only after pre-filtering
the covariates.
Keywords Clinical trials · High-dimensional data · Innovative design ·Multiple outcomes · Precision medicine · Risk
scores.
1 Introduction
It is common in clinical trials that only a subgroup of treated patients is likely to benefit from an experimental therapy
[1, 2, 3, 4]. This creates the need to better design and analyse clinical trials so they provide more information about
which patients, if any, benefit from a treatment. For this purpose, high-dimensional information that is increasingly
being collected on patients can be used.
There have been several approaches proposed for utilising (potentially high-dimensional) treatment by covariate
interactions to stratify patients. For example, [5] and [6] proposed an adaptive signature design (ASD) that combines
a prospective development of a sensitive patient classifier and validation of the classifier in a single trial, based on
treatment-covariate interactions obtained via regression modelling.
Motivated by the work of [5] and [6], [7] focus on subgroup selection using baseline covariates by incorporating a utility
function that takes into account the size of a subgroup or the possibility for an alternative treatment for the patients.
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In the randomised clinical trial of evaluation of the effects of the dose of dialysis and the level of flux of the dialyser
membrane on time to death from any cause [8], the method identified a subgroup with a significantly greater treatment
difference.
Another approach to handling treatment-covariate interactions is decision tree algorithms [9, 10, 11]. These algorithms
recursively partition the data with splits chosen to optimize an objective function. The algorithms differ in the size of
the search space [11], the order of the splitting variables [10], the selection of covariates and the choice of the optimal
cut-off [12, 13], and preventing bias in the variable selection by fitting a parametric model to the data in each node of
the tree in a model-based recursive partitioning approach [14, 15, 16, 17]. “Virtual twins” [2] is another tree-based
approach that involves computing the difference between predicted response probabilities for the treatment subject and
its control “twin”. [18] proposed estimating treatment by covariate interactions using a modified covariate approach
without the need for modeling the main effects. [19] tested the existence of subgroups with differential treatment effects
by utilising the association between the subgroup membership and subject-specific covariates in a logistic-normal
mixture model framework. A few studies have considered the compound covariate predictor approach for the prediction
of predefined tumour classes [20], for quantitatively estimating treatment effects and for predicting survival curves
[21, 22]. In the compound covariate predictor approach, the compound covariate was constructed using a test statistic
from treatment-covariate interactions. [3] selected the subgroups via a variety of parametric scoring systems that were
constructed as a function of multiple baseline covariates and were used to estimate the treatment difference. [23]
utilised gene-expression profiles to identify subgroups of patients with different survival rates, while the subgroups with
distinctive gene-expression profiles were defined on the basis of hierarchical clustering.
All these methods have been proposed for a single endpoint. However, in many clinical trials, multiple outcomes are of
interest. This is especially relevant for clinical trials that analyse both efficacy and toxicity of the treatment (common
in oncology and in other areas where treatment can have considerable side effects), efficacy and quality of life, and
cost effectiveness of new drugs and treatments in health economics. For example, [24] considered the appropriate
subpopulation for a clinical trial which was defined by a single biomarker that exceeded a specified threshold value. In
addition to the main outcome that represented a response to the treatment, they proposed to incorporate other outcomes
such as risk or cost associated with a new treatment by optimising population impact.
The cross-validated risk scores (CVRS) method [25] is based on constructing risk scores from a large number of
baseline covariates. Risk scores represent a scoring system that is developed to be associated with the treatment effect
and that can be used for predicting a benefit from the treatment. The CVRS design consists of two steps. In the first step,
a single-response regression model is fit to every covariate and the risk scores are constructed as sums of associated
covariates within each patient weighted by their estimated effects. In the second step, the risk scores are divided into two
clusters that correspond to sensitive and non-sensitive groups of patients. Similarly to the cross-validated ASD [6], the
sensitive group is the subgroup of patients predicted to have high treatment effect. The method has been implemented
in an R package rapids [26].
In this article, we propose the extension of the CVRS method that considers two outcomes, i.e. a design that develops a
signature from a large number of covariates, considering two endpoints. The proposed CVRS2 method utilises vector
generalized linear models [27] for constructing bivariate risk scores. The bivariate risk scores are then divided into a
prespecified number of clusters using an extension of the clustering procedure that has been used for the CVRS method.
This clustering procedure is computationally straightforward and can be used as a starting point (we discuss other
clustering procedures in the Discussion section). We explore the operating characteristics of the CVRS2 method for
simulation scenarios that assume two outcomes that have different correlation structures. We also have extended the R
package rapids to incorporate the CVRS2 method. To our knowledge, CVRS2 is the first method within the adaptive
signature design family that considers two outcomes.
The remainder of this paper is organised as follows. The Methods section briefly describes the original CVRS design
and introduces the CVRS2 design. In the Results section, we explore the operating characteristics of the CVRS2 design
for various simulation scenarios. In the Real Data Example section, we illustrate the application of the CVRS2 design
to a randomised psychiatry clinical trial. Finally, we summarise our conclusions in the Discussion section.
2 Methods
2.1 CVRS Design
The full details of the method are provided in [25]. Briefly, the model assumes that the response to treatment denoted
by Y is influenced by a subset of K unknown covariates (the sensitive covariates) though a generalised linear model.
2
A PREPRINT - JULY 6, 2020
For example, for a binary outcome, the model looks as follows:
log
(
pi
1− pi
)
= µ+ λti + α1xi1 + · · ·+ αKxiK + γ1tixi1 + · · ·+ γKtixiK ,
where pi is the probability of the response to treatment for the ith patient; µ is the intercept; λ is the treatment main
effect that all patients experience regardless of the values of the covariates; ti is the treatment that the ith patient
receives (ti = 0 for the control arm and ti = 1 for the treatment arm); xi1, . . . , xiK are the values for the K unknown
sensitive covariates; α1, . . . , αK are main covariate effects for the K covariates; γ1, . . . , γK are the treatment-covariate
interaction effects for the K covariates. The model assumes that there is a subset of patients (the sensitive group) with a
higher probability of response when treated with the new treatment compared with the control treatment.
In the first step of the CVRS design, a signature is developed by constructing risk scores within each patient as sums of
associated covariates weighted by their estimated effects. In the second step, a clustering procedure is applied to divide
the risk scores into two clusters that correspond to sensitive and non-sensitive groups of patients. For constructing the
risk scores, the cross-validation procedure is used, in which the model is built using the training subset and the risk
scores are constructed for the patients in the test subset set as follows. For r-fold cross-validation, the observed dataset
D of size N is randomly divided into r non-overlapping subsets D(l), l = 1, . . . , r, of (approximately) equal size N/r.
A common choice of r is 10 which we adopt here. For each iteration of the r-fold cross-validation, data are split into
test D(l) and training D(−l) (formed by removing D(l) from D) subsets and the coefficients for treatment by covariate
interaction βˆ(−l)j are estimated for each covariate j from Equation 1 using training subset alone.
log
(
pi
1− pi
)
= µ+ λti + αjxij + βjtixij (1)
Then, for each test set D(l), the risk scores are computed as RS(l)i =
∑
j βˆ
(−l)
j x
(l)
ij , where x
(l)
ij is the value of the
covariate j for the ith patient in the lth test set. Within each test set D(l), the k-means procedure ([28]) with k = 2 is
applied to classify the test scores RS(l)i , i = 1, . . . , N/r into sensitive and non-sensitive groups. Therefore, at the end
of the cross-validation process each patient in the observed data D is classified either as sensitive or non-sensitive, after
pooling group membership status across the r test sets.
There are a few ways that one can test for the difference between the arms. One way is to consider the overall test
positive if there is either a significant difference in the overall comparison between the arms or a significant difference
between the arms in the sensitive group. The test for the overall comparison between the arms could be performed using
a test for the difference of two proportions, carried out at a significance level α1, while for the comparison between the
arms within the sensitive subgroup only Fisher’s exact test could be carried out at a significance level α2. The overall
type I error is controlled at the significance level α = α1 + α2. Alternatively, one can test for the interaction effect
between the treatment and the sensitivity status using a generalised linear model. Generally, it is advisable to use a
permutation method to obtain a P -value for testing the interaction effect between the treatment and the sensitivity status
[29] because when the sensitive group is obtained by cross-validation, the samples are not independent and therefore
the standard asymptotic theory does not apply. In the permutation method, the entire cross-validation procedure is
performed for every permuted data set and the corresponding test statistic is obtained. The one-sided permutation
P -value is given by
1 + number of elements of P ∗ ≤ P0
1 + number of permutations
, (2)
where P ∗ is the vector of the P -values for the treatment-sensitivity status interaction effect computed for a large
number of permuted data sets, and P0 is the P -value for the treatment-sensitivity status interaction effect obtained for
the original (non-permuted) data.
2.2 CVRS2 Design
The CVRS2 design considers two outcomes, Y1 and Y2 (e.g. these could represent efficacy and toxicity in cancer
clinical trials), that are influenced by a subset of K unknown covariates (the sensitive covariates) through a vector
generalized linear model [27]. For example, the relationships between two binary outcomes and sensitive covariates can
be described through a bivariate odds ratio model [30] as follows:
log
(
p
(1)
i
1− p(1)i
)
= µ(1) + λ(1)ti + α
(1)
1 xi1 + · · ·+ α(1)K xiK + γ(1)1 tixi1 + · · ·+ γ(1)K tixiK (3)
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log
(
p
(2)
i
1− p(2)i
)
= µ(2) + λ(2)ti + α
(2)
1 xi1 + · · ·+ α(2)K xiK + γ(2)1 tixi1 + · · ·+ γ(2)K tixiK (4)
log(ψi) =
p
(1)
i
1−p(1)i
|p(2)i = 1
p
(1)
i
1−p(1)i
|p(2)i = 0
,
where p(1)i is the probability of the first outcome (Y1) for the ith patient, p
(2)
i is the probability of the second outcome
(Y2) for the ith patients, ψ is the odds ratio of Y1 = 1 when Y2 = 1 relative to when Y2 = 0. A measure that describes
the association between the two proportions, ψ, is modelled as intercept-only, which is equivalent to the assumption
of constant correlation. A more complex modelling of ψ that allows for more flexible correlation structures can be
used. However in some cases these may lead to numerical problems [30]. Here, the estimated correlation between the
outcomes is not explicitly used in the analysis. However, taking the correlation into account by jointly modelling the
outcomes allows us to better estimate the effects of the covariates.
For constructing the risk scores, the coefficients for treatment by covariate interaction are estimated for each covariate j
from a single-covariate bivariate odds ratio model:
log
(
p
(1)
i
1− p(1)i
)
= µ(1) + λ(1)ti + α
(1)
j xij + β
(1)
j tixij
log
(
p
(2)
i
1− p(2)i
)
= µ(2) + λ(2)ti + α
(2)
j xij + β
(2)
j tixij
log(ψi) =
p
(1)
i
1−p(1)i
|p(2)i = 1
p
(1)
i
1−p(1)i
|p(2)i = 0
,
Similarly to the CVRS design, the cross-validation procedure is used for obtaining the bivariate risk scores which are
computed for each patient i as RS(l)i = {
∑
j
βˆ
(−l,1)
j x
(l)
ij ,
∑
j
βˆ
(−l,2)
j x
(l)
ij } for each iteration of the r-fold cross-validation
procedure. Here, the first score is computed with respect to the first outcome, while the second score is computed with
respect to the second outcome. The bivariate risk scores can be partitioned into a number of clusters within each test set
D(l), similarly to the CVRS design.
In some settings, e.g. where a treatment could be either (i) safe and effective; (ii) not safe and not effective; (iii) safe
and not effective; (iv) effective and not safe, the most natural choice for the number of clusters is four. Letting the rate
of the first response represent the efficacy of the treatment and the rate of the second response represent the safety of
the treatment, the four clusters would represent (i) participants that have high response rates for both outcomes; (ii)
participants that have low response rates for both outcomes, (iii) and (iv) participants who have a high response rate for
one of the outcomes and a low response rate for the other. This division can be accomplished by applying the k-means
clustering procedure with k = 4. Here, a sensitive group can be defined as one of the clusters or a combination of the
clusters.
In settings where a treatment would have to be either sufficiently safe and effective or not safe and not effective (i.e.
when there are only two underlying clusters of patients), it may make better sense to divide patients into two groups.
Here, the first group would represent participants with high response rates for both outcomes, while the second group
would represent participants with low response rates for both outcomes. In this case, the k-means is applied with k = 2.
We note that k-means clustering with k = 2 may not necessarily divide patients into two clusters with this interpretation.
We explore this in the results and consider alternatives in the discussion.
For each outcome, the power to conclude treatment effect in the trial population and the power to conclude treatment
effect in the sensitive group are computed. We also consider the overall power to reach at least one of these conclusions.
For the power in the trial population, we compute the probability to detect a significant effect in the first outcome and
the probability to detect a significant effect in the second outcome, i.e. P tp = {P tpi } where i = 1, 2 is the outcome.
In the four cluster case, for each outcome, we compute the power for the sensitive group as a set of four elements,
each element represents the probability to detect a significant difference between the treatment and the control in each
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one of the clusters, i.e. P sensi = {P sensi1 , P sensi2 , P sensi3 , P sensi4 }, where i = 1, 2 is the outcome. The overall power,
P ovi = {P ovi1 , P ovi2 , P ovi3 , P ovi4 }, which represents the probability of a significant result for either the trial population or
the sensitive group, is computed as follows:
P ovi = {P ovi1 , P ovi2 , P ovi3 , P ovi4 } = P tp + (1− P tp)× P sensi =
{P tpi + (1− P tpi )× P sensi1 , P tpi + (1− P tpi )× P sensi2 , P tpi + (1− P tpi )× P sensi3 , P tpi + (1− P tpi )× P sensi4 }.
2.3 Simulation study
We conducted a simulation study to evaluate the performance of the CVRS2 for four scenarios, exploring a different
number of subgroups and the correlation between the covariates. For every scenario, we assumed a clinical trial with
100 covariates where K=10 of them are sensitive for each outcome with an overlap of five sensitive covariates, i.e.
there were five covariates that were sensitive to both outcomes. The main effects of the covariates were assumed
to be 0, and the treatment-covariate interaction effects were assumed to be constant across the sensitive covariates,
similarly to [25]. The intercepts µ(1) and µ(2) were set to correspond to control arm response rates of 25%. We used
an overall significance level α = 0.05 (two-sided) that corresponds to α1 = 0.04 and α2 = 0.01 significance levels for
the trial population test and for the sensitive group test, respectively, as suggested in [5]. The empirical overall power
was calculated as the percentage of replications with either a positive trial population 0.04 level test or a positive 0.01
level sensitive group test. The results of the simulations were based on 1000 replications. The parameters used in the
simulation study are presented in Table 1. In all of the scenarios, the response rates and the sample sizes correspond
to those used in [5] and [25]. A detailed description of how data were simulated is given in Supplementary Material.
We note that there is no direct comparator method that we are aware of for the two outcome case, hence we are
comparing the CVRS2 method to the original CVRS method applied separately to each one of the outcomes, for both
the simulations and the real data example.
3 Results
3.1 Scenario I
The data were simulated assuming that there was a group of patients that had high rates of both responses Y1 and Y2
(the sensitive group), while the rest of the patients had low rates of both responses (the non-sensitive patients). Here, by
response rate we denote the probability that the response takes the value of 1. The rates of Y1 and Y2 were 0.7 and
0.25 for the sensitive and the non-sensitive group, respectively (the response rates are illustrated in Figure 1(a) for 10
simulations runs). The percentage of patients in the sensitive group were either 10% or 20%, the sample size was 400.
The data were simulated assuming an independence between the covariates. The results are presented in Table 2. The
resultant risk scores are illustrated in Figure 2(a) for 10 simulation runs. The risk scores show a perfect separation
between the sensitive and the non-sensitive groups, and the response rates in both sensitive and non-sensitive groups are
estimated with a high precision(estimated rates of Y1 and Y2 for the sensitive and non-sensitive group were 0.69 and
0.25, respectively).
3.2 Scenario II
The data were simulated assuming four clusters of patients, which represent (i) patients with low response rates for both
responses (cluster 1); (ii) and (iii) patients with a high response rate for one of the responses and a low response rate for
the other, and vice versa (clusters 2 and 3); and (iv) patients with high response rates for both responses (cluster 4), as
explained in Section 2.2. This scenario covers three sub-scenarios, IIa, IIb and IIc. In all three of the sub-scenarios
the low response rate is 25%, while the high response rate is 80% for scenario IIa, 70% for scenario IIb and 60% for
scenario IIc. The response rates are illustrated in Figure 1(b-d) for 10 simulation runs. The mean rates of Y1 and Y2
for cluster 1 were 25% for all three of the sub-scenarios. In Scenario IIa, the mean rate of Y1 for clusters 3 and 4 was
80%, and the mean rate of Y2 for clusters 2 and 4 was 80%. For Scenarios IIb and IIc, these mean response rates were
70% and 60%, respectively (see Table 1). The covariates were assumed to be independent. The results are presented in
Table 3 for sample sizes 400 and 1000. For each scenario we investigated the method assuming that the sensitive group
corresponds to one cluster in turn, as elaborated in Section 2.2. The risk scores for Scenario IIa are illustrated in Figure
2(b) for 10 simulation runs. The sensitivity and specificity of identifying the sensitive group are high reaching values >
0.95 in many cases. Interestingly, the response rates are better estimated for clusters 1 and 4 rather than for clusters 2
and 3. This is in line with the results for Scenario I, suggesting that the method estimates the sensitive group better
for clusters where the rates of both responses are similar. Very low power for the sensitive group test when cluster 1
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corresponds to sensitive group suggests that the type I error is well controlled: considering cluster 1 as the sensitive
group is equivalent to a null scenario.
3.3 Scenario III
To investigate the sensitivity of the CVRS2 method to the data generating mechanism, we simulated data assuming a
moderate pairwise correlation (ρ = 0.4) between all covariates. In this scenario, the data were simulated assuming four
clusters of patients, with the low response rate being 25% and the high response rate being 80%, similarly to scenario
IIa. The only difference with scenario IIa is the correlation between the covariates. The response rates are illustrated
in Figure 1(e) for 10 simulation runs. Clearly, there is an increased variability of the cluster-wise response rates in
comparison to scenarios with independent covariates (see Figure 1(b) for comparison). The results are presented in
Table 3. The risk scores are illustrated in Figure 2(c) for 10 simulation runs. Lower sensitivity and specificity values in
comparison to scenario IIa (where ρ = 0) suggest that the method would benefit from pre-filtering of the covariates
based on the correlation between them. However, even without modelling the correlation between the covariates the
method was still able to increase the overall power beyond that achieved for the trial population 0.04 level test.
3.4 Scenario IV
The data were simulated assuming a null scenario where the rates of both responses Y1 and Y2 in all patients on both
arms are 25%. The results are presented in Table 3. The risk scores are illustrated in Figure 2(d) for 10 simulation runs.
The results show that a type I error is well controlled at the 0.01 level for the sensitive group test and at the 0.05 level
overall. The response rates are estimated with high precision, being very close to 0.25 for all clusters (see Table 3).
3.5 Comparison between CVRS2 and CVRS
In order to compare the performance of the CVRS2 with the CVRS, we applied the CVRS to each one of the responses
separately (we refer to this method as marginal CVRS). For the marginal CVRS, patients that were non-sensitive to
both outcomes were referred to as cluster 1, patients that where sensitive to one of the outcomes were referred to as
clusters 2 and 3, and patients that where sensitive to both outcomes were referred to as cluster 4.
To illustrate the difference in the results between the CVRS2 and the marginal CVRS, we used three randomly selected
simulation replicates with different correlations between the response rates. The correlation between the response rate
was induced by the covariates that affect both responses (the overlapping covariates). All three of the data sets were
simulated similarly to scenario IIb, i.e. the high response rate was 0.7, the sample size was 1000, the number of sensitive
covariates was 10 for either response. The numbers of the overlapping covariates were zero, five and nine leading to
estimated correlations of -0.003, 0.24 and 0.46, respectively. We applied the CVRS2 and the marginal CVRS to each
data set. The results as shown by the risk scores coloured by the predicted and true clusters are illustrated in Figure
3(a) for zero overlapping covariates, Figure 3(b) for five overlapping covariates and Figure 3(c) for nine overlapping
covariates. The marginal CVRS separates the risk scores into four clusters as follows. Each one of the marginal CVRS
analyses identifies two clusters, Cij , where i = 1, 2 represents the responses and j = 1, 2 represents the clusters.
Suppose j = 1 represents the cluster of patients that benefit from the treatment. Patients with low response rates for
both responses (cluster 1) are represented by C12 ∧ C22, patients with a high response rate for one of the responses and
a low response rate for the other (clusters 2 and 3) are represented by C12 ∧ C21 and C11 ∧ C22, and patients with high
response rates for both responses (cluster 4) are represented by C11 ∧ C21, where the symbol ∧ denotes an intersection.
In the case of zero overlapping covariates, the CVRS2 perfectly separated the clusters, while the marginal CVRS did not
perform as well. In the case of five overlapping covariates, the CVRS2 had a much better ability to classify the patients
in comparison to the marginal CVRS that failed to separate clusters 2, 3 and 4. However, in the case of nine overlapping
covariates both designs were unable to classify the patients correctly into four clusters. This can be explained by the
fact that a higher correlation between the response rates makes the data more compatible with two clusters than four, as
illustrated by the risk scores. Interestingly, the marginal CVRS successfully differentiated between the two clusters of
the data. When we applied the CVRS2 with k = 2 to this data set, the design was able to perfectly separate the two
underlying clusters, similarly to the marginal CVRS (Supplementary Figure 3).
4 Real Data Example
Previously, we have applied the CVRS method to the data from the Systematic Therapy of At Risk Teens (START)
[31]. START was a randomised controlled trial comparing the outcomes of young people and their families who were
allocated to treatment as usual (control arm) and multisystemic therapy (treatment arm). The data set comprised of
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669 participants (336 participants in the control arm and 333 participants in the treatment arm) and 86 covariates.
Participants with one or more offences were defined as offenders (288 in total; 143 in the control arm and 145 in the
treatment arm), while participants with no offences were defined as non-offenders (381 in total; 193 in the control
arm and 188 in the treatment arm). No overall significant treatment effect as measured by a logistic regression was
detected (P = 0.797). The CVRS method indicated the existence of a sensitive group comprised of 453 participants
(222 participants in the control arm and 231 participants in the treatment arm) with no significant interaction effect
between the treatment and the sensitivity status (permutation-based P = 0.122). However, a marginally significant
interaction effect between the treatment and the sensitivity status (P = 0.043) was achieved after a pre-filtering of the
covariates based on a P -value threshold.
Here, we analyse the START data considering two outcomes: in addition to the previously analysed offender/non-
offender status, we analyse a binary substance use status (the numbers of the offenders/substance users are presented
in Supplementary Table 1). Due to missingness of the substance use status in above 30% of participants, the two
outcome dataset comprises of 461 participants (218 participants in the control arm and 243 participants in the treatment
arm). The analysis was performed without the pre-filtering of the covariates. No overall significant treatment effect
as measured by a bivariate odds ratio model was detected (P = 0.993 and P = 0.181 for the offender status and the
substance use status, respectively). We analysed the START data with the CVRS2 method assuming either two or four
underlying clusters (see Supplementary Figure 1 for the corresponding risk scores). For the two-cluster analysis, the
CVRS2 method found a sensitive group comprised of 283 participants (132 participants in the control arm and 151
participants in the treatment arm). The permutation-based P values for the interaction between the treatment and the
sensitivity status were 0.003 and 0.129 with respect to the offender status and the substance use status, respectively
(based on 2000 permutations). For the four-cluster analysis, the permutation-based P -value was computed assuming
one cluster in turn corresponds to a sensitive group. With respect to the offender status, the cluster-wise permutation
P -values were 0.007, 0.147, 0.023 and 0.162, while with respect to the substance use, the cluster-wise permutation
P -values were 0.038, 0.193, 0.509 and 0.299. The estimated cluster-wise rates for the offender status were 0.27, 0.36,
0.44 and 0.49, while the estimated cluster-wise rates for the substance use status were 0.23, 0.4, 0.36 and 0.43. The size
of the clusters were 67, 132, 151, and 111 subjects. The mean offender rate and substance use rate in each arm within
each cluster are shown in Supplementary Table 3.
In order to compare the CVRS2 with the CVRS, we applied the marginal CVRS to the two outcome dataset that
comprises of 461 patients. The permutation-based P -values for the interaction effect between the treatment and the
sensitivity status were P = 0.101 and P = 0.383 with respect to the offender status and the substance use status,
respectively (Supplementary Figure 2). The coefficients of the covariates that contributed to the risk scores are presented
in Supplementary Table 4 for the CVRS2 method and in Supplementary Table 5 for the marginal CVRS method.
5 Discussion
We have proposed a method that can stratify patients into groups that have different treatment effects on more than
one outcome. This method represents a modification of the CVRS design. The new CVRS2 design considers two
outcomes and utilises bivariate risk scores. The scores are constructed as sums of the covariates weighted by their
coefficients, estimated with vector generalised linear models. We have investigated the performance of the CVRS2
method by applying it to various simulated scenarios. We found that when the data is clearly divided into two subgroups
of samples (sensitive and non-sensitive), the method is able to perfectly separate between the groups. When the data
consists of four clusters (two clusters with both high/low rates of responses, and two clusters with a high rate of one of
the responses and a low rate of the other), the method is able to identify the clusters and to estimate the rates of the
responses reasonably well. We showed that in the case of four clusters, increasing the sample size, as well as increasing
the rate of one the high response improves the performance of the method. This suggests that it would be better to
reverse the toxicity endpoint to “non-toxicity” if the aim is to find a group that has high efficacy and low toxicity.
We investigated the correlation between the response rates in the sensitive groups on treatment by simulating the data
with different numbers of overlapping covariates (zero, five and nine). We found that in the cases of zero and five
overlapping covariates, the CVRS2 design performs better than the marginal CVRS design (the original one outcome
CVRS that has been applied to each outcome separately). However, when the number of the overlapping covariates
is too large (nine out of ten in our case), both methods are unable to identify four clusters, because the data are more
compatible with two clusters. This suggests that the method is sensitive to the prior assumption about the number of the
true clusters.
To illustrate the applicability of the methods to the real data, we have applied it to the data from a START randomised
controlled trial. Here we considered the offender status and the substance use status as two outcomes. We showed that
the CVRS2 was able to identify a sensitive group that conferred a significant interaction effect (P = 0.003) between
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the treatment and the sensitivity status (with respect to the offender status), assuming the data consist of two groups
of participants (interestingly, the interaction effect between the treatment and the sensitivity status with respect to
substance use was not significant: P = 0.129). This is in contrast to the CVRS method that considers one outcome only,
which did not identify a sensitive group that conferred a significant interaction effect between the treatment and the
sensitivity status. This shows that incorporating information from an additional outcome could marginally improve
the results for the first outcome, even though the results for the second outcome are not significant. We next analysed
the START data assuming there are four clusters of participants. The results showed a significant interaction effect
between the treatment and the sensitivity status with respect to the offender status when cluster 1 is assumed to belong
to a sensitive group (P = 0.007). The corresponding P -value for the substance use achieved a nominal significance as
well (P = 0.038). The estimated response rates for the cluster with the highest response rates (0.49 and 0.42) were
lower than those of the simulated data. This suggests that for the real data with higher response rates for the sensitive
group, the method would achieve more significant results. Additionally, a larger data set would achieve a higher power
as illustrated for the simulated data.
We compared the results for the CVRS2 design with the results for the marginal CVRS for the same set of patients.
We showed that the marginal CVRS was not able to find a significant interaction effect between the treatment and the
sensitivity status with respect to both offender status and substance use status. This result is in line with the result
for the simulated data that showed a better classification ability for the CVRS2 in comparison to the marginal CVRS.
Interestingly, the risk scores for the CVRS2 and for the marginal CVRS are driven by different covariates, as can be
seen from Supplementary Tables 4 and 5. The covariates that have the largest absolute values of the coefficients for
the marginal CVRS, have coefficients equal to zero for the CVRS2 (for example, a diagnosis of eating disorder). The
difference in the contribution of the covariates to the risk scores in the two methods could explain the difference in the
assignment to the clusters. While the clinical interpretation of the covariates is beyond the scope of the manuscript, it
could facilitate further independent investigation.
We note that CVRS method was able to achieve a significant result for the real data only after a pre-filtering of the
covariates based on a P -value threshold. Here, by taking an additional outcome into account, the CVRS2 method
achieved a significant result without applying any pre-filtering of the covariates, even for a smaller sample size. However,
the simulation results show that when the covariates are correlated, the method might benefit from the pre-filtering of
the covariates based on the correlation between them, which will be investigated in future work. An additional issue
that requires further investigation is the number of clusters. We have investigated the cases of two and four clusters. Yet,
for the four-cluster case, one might want to investigate merging some of the clusters together into a sensitive group. In
practice, the assumption of the number of the clusters might also depend on the nature of the study and the question to
be analysed. Finding the optimal number of clusters would be a part of future research. Similarly to the CVRS method,
in this study, we have retrospectively applied the CVRS2 method to identify the sensitive group in psychiatry trial
participants. In principle, the method can be used to prospectively identify whether a participant belongs to a sensitive
group.
To divide the patients into clusters, we utilised a computationally straightforward and scalable k-means clustering
procedure that works well in practice [32]. For example, k-means clustering has been used previously in the context of
gene expressions, where it successfully separated the high-risk versus low-risk cutoff for the up-/down-regulated mean
ratio of gene expressions [33]. However, we note that different clustering algorithms can be utilised. For instance, [23]
utilised hierarchical clustering to analyse genes whose expression was correlated with the outcomes.
In this study, we applied a supervised clustering approach, i.e. the number of clusters was pre-specified. This approach
requires prior knowledge about the most plausible number of clusters, as shown in Section 3.5. Future work will
investigate the performance of the unsupervised clustering approaches, where the number of clusters is unknown a
priori. Additional areas to explore are the parametric clustering approach in which each cluster is assumed to follow a
parametric distribution and the data is modelled with a mixture model [34], and the semiparametric clustering approach
that models high-density data with a parametric density and low-density data with a non-parametric density [35].
6 Software
We extended the R package rapids [26] to incorporate the CVRS2 method. As with the CVRS, the CVRS2 method
is developed for binary outcomes. The package now includes three additional main functions: simulate.data2,
analyse.simdata2 and analyse.realdata2 for simulating data, analysing the simulated data and analysing real data.
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Figure 1: The response rates on treatment for the simulated data for (a) scenario I, (b) scenario IIa, (c) scenario IIb, (d)
scenario IIc, (e) scenario III.
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Figure 2: The risk scores for (a) scenario I, (b) scenario IIa, (c) scenario III, (d) scenario IV.
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Figure 3: The risk scores for the marginal CVRS and the CVRS2 for the scenarios with (a) 0 overlapping covariates; (b)
5 overlapping covariates; (c) 9 overlapping covariates.
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Table 1: Parameters that are used in simulation study. Each row corresponds to a simulated scenario. Column θi, σ2i , ρi
corresponds to the mean, variance and correlation of multivariate normal distribution that was used to simulate sensitive
covariates in the subgroups that are sensitive to outcome i = 1, 2. Column νi, ζ2i , κi corresponds to the mean, standard
deviation and correlation of multivariate normal distribution that was used to simulate sensitive covariates in the
subgroups that are not sensitive to outcome i = 1, 2. Column η, ξ2, τ corresponds to the mean, standard deviation and
correlation of multivariate normal distribution that was used to simulate the rest of the covariates in all patients. For
each cluster of patients, the columns RR1 and RR2 correspond to the rates of response 1 and response 2, respectively.
Cluster 1 Cluster 2 Cluster 3 Cluster 4
Scenario θi, σ2i , ρi νi, ζ
2
i , κi η, ξ
2, τ RR1 RR2 RR1 RR2 RR1 RR2 RR1 RR2
1 1, 0.25, 0 0, 0.01, 0 0, 0.25, 0 0.25 0.25 0.7 0.7 - - - -
2a 1, 0.25, 0 0, 0.01, 0 0, 0.25, 0 0.25 0.25 0.25 0.8 0.8 0.25 0.8 0.8
2b 1, 0.25, 0 0, 0.01, 0 0, 0.25, 0 0.25 0.25 0.25 0.7 0.7 0.25 0.7 0.7
2c 1, 0.25, 0 0, 0.01, 0 0, 0.25, 0 0.25 0.25 0.25 0.6 0.6 0.25 0.6 0.6
3 1, 0.25, 0.4 0, 0.01, 0.4 0, 0.25, 0.4 0.25 0.25 0.25 0.8 0.8 0.25 0.8 0.8
4 1, 0.25, 0 0, 0.01, 0 0, 0.25, 0 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25
Table 2: Operating characteristics of the CVRS2 methods for scenario I. The response rates on the control arm are 25%.
10 covariates are sensitive to response 1, 10 covariates are sensitive to response 2 with the overlap of 5 covariates. The
results are based on 1000 simulations.
Sensitive group
Operating characteristics 10% 20%
Power in the trial population (w.r.t. response 1) 0.123 0.460
Power in the trial population (w.r.t. response 2) 0.125 0.446
Power in the sensitive group (w.r.t response 1) 0.515 0.892
Power in the sensitive group (w.r.t. response 2) 0.469 0.906
Overall power (w. r. t. response 1) 0.571 0.934
Overall power (w. r. t. response 2) 0.523 0.941
Sensitivity of the group selection 0.999 1.000
Specificity of the group selection 0.999 1.000
Estimated rate of response 1 in sensitive group 0.694 0.689
Estimated rate of response 2 in sensitive group 0.689 0.693
Estimated rate of response 1 in non-sensitive group 0.250 0.251
Estimated rate of response 2 in non-sensitive group 0.251 0.251
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Table 3: Operating characteristics of the CVRS2 method for scenarios II, III and IV. The response rates on the control
arm are 25%. 10 covariates are sensitive to response 1, 10 covariates are sensitive to response 2 with the overlap of 5
covariates. Each one of the clusters 2, 3, 4 comprise of 10% of patients. The results correspond to sample size 400.
The results in the parentheses correspond to sample size 1000. The power for the tiral population 0.04 level test w. r. t.
response 1 and response 2, respectively is: 0.595(0.956) and 0.596(0.956) for scenario IIa; 0.427(0.835) and 0.43(0.842)
for scenario IIb; 0.289(0.604) and 0.2943(0.594) for scenarion IIc; 0.961 and 0.951 for scenario III; 0.037 and 0.044 for
scenario IV.
Sensitive group corresponds to:
Sc
en
ar
io
Operating characteristics Cluster 1 Cluster 2 Cluster 3 Cluster 4
IIa
Power in the sensitive group (w. r. t. resp. 1) 0.007(0.009) 0.010(0.017) 0.606(0.998) 0.751(0.998)
Power in the sensitive group (w. r. t. resp. 2) 0.004(0.010) 0.441(0.998) 0.067(0.025) 0.581(0.997)
Overall power (w. r. t. response 1) 0.599(0.956) 0.599(0.956) 0.829(1.000) 0.889(1.000)
Overall power (w. r. t. response 2) 0.597(0.957) 0.766(1.000) 0.619(0.957) 0.826(0.999)
Sensitivity of the group selection 0.925(1.000) 0.779(0.964) 0.776(0.953) 0.790(0.877)
Specificity of the group selection 0.999(0.999) 0.927(0.992) 0.962(0.990) 0.980(0.995)
Estimated rate of response 1 0.250(0.251) 0.287(0.279) 0.695(0.774) 0.788(0.791)
Estimated rate of response 2 0.250(0.252) 0.597(0.775) 0.402(0.283) 0.719(0.786)
IIb
Power in the sensitive group (w. r. t. resp. 1) 0.008(0.004) 0.019(0.023) 0.297(0.938) 0.548(0.951)
Power in the sensitive group (w. r. t. resp. 2) 0.010 (0.011) 0.124(0.933) 0.107(0.029) 0.389(0.955)
Overall power (w. r. t. response 1) 0.431(0.836) 0.437(0.838) 0.589(0.988) 0.734(0.992)
Overall power (w. r. t. response 2) 0.435(0.846) 0.498(0.988) 0.489(0.845) 0.663(0.991)
Sensitivity of the group selection 0.800(0.997) 0.544(0.928) 0.711(0.909) 0.782(0.846)
Specificity of the group selection 0.999(0.999) 0.830(0.986) 0.937(0.984) 0.970(0.993)
Estimated rate of response 1 0.248(0.251) 0.274(0.282) 0.558(0.671) 0.687(0.698)
Estimated rate of response 2 0.251(0.252) 0.403(0.661) 0.433(0.300) 0.621(0.684)
IIc
Power in the sensitive group (w. r. t. resp. 1) 0.005(0.006) 0.009(0.023) 0.115(0.699) 0.348(0.773)
Power in the sensitive group (w. r. t. resp. 2) 0.010(0.013) 0.023(0.543) 0.108(0.077) 0.224(0.729)
Overall power (w. r. t. response 1) 0.292(0.607) 0.296(0.612) 0.364(0.871) 0.530(0.901)
Overall power (w. r. t. response 2) 0.301(0.600) 0.309(0.815) 0.365(0.627) 0.444(0.882)
Sensitivity of the group selection 0.658(0.951) 0.310(0.805) 0.639(0.845) 0.760(0.821)
Specificity of the group selection 0.996(0.999) 0.731(0.946) 0.906(0.969) 0.955(0.989)
Estimated rate of response 1 0.250(0.250) 0.262(0.284) 0.446(0.550) 0.581(0.600)
Estimated rate of response 2 0.253(0.252) 0.298(0.504) 0.428(0.325) 0.527(0.588)
III
Power in the sensitive group (w. r. t. response 1) 0.010 0.018 0.789 0.990
Power in the sensitive group (w. r. t. response 2) 0.014 0.201 0.691 0.907
Overall power (w. r. t. response 1) 0.955 0.955 0.990 0.999
Overall power (w. r. t. response 2) 0.945 0.953 0.981 0.994
Sensitivity of the group selection 0.631 0.317 0.573 0.662
Specificity of the group selection 0.985 0.718 0.890 0.949
Estimated rate of response 1 0.250 0.278 0.540 0.736
Estimated rate of response 2 0.254 0.343 0.511 0.657
IV
Power in the sensitive group (w. r. t. response 1) 0.012 0.011 0.008 0.010
Power in the sensitive group (w. r. t. response 2) 0.006 0.004 0.012 0.009
Overall power (w. r. t. response 1) 0.048 0.047 0.044 0.047
Overall power (w. r. t. response 2) 0.050 0.047 0.055 0.052
Sensitivity of the group selection 0.223 0.273 0.264 0.306
Specificity of the group selection 0.744 0.736 0.732 0.773
Estimated rate of response 1 0.248 0.249 0.249 0.252
Estimated rate of response 2 0.252 0.248 0.251 0.249
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Supplementary Figure 1. The risk scores for the START data with the CVRS2 method assuming (a) two underlying
clusters; (b) four underlying clusters.
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Supplementary Figure 2. The risk scores for the START data with the marginal CVRS method that was applied to the
two outcome dataset (461 participants) with respect to the (a) offender status; (b) substance use status.
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Supplementary Table 1. Number of the participants in the START trial.
Outcome 2
Number of substance users Number of substance non-users
Outcome 1 Number of offenders 52 (control); 47 (treatment) 36 (control); 51 (treatment)Number of non-offenders 43 (control); 44 (treatment) 87 (control); 101 (treatment)
Supplementary Table 2. Parameters of the multivariate normal distribution to simulate gene expression values for
different statuses of subjects/covariates. Si ∈ {0, 1} for i = 1, 2 is the sensitivity status of a subject with respect to the
outcome i. Ki ∈ {0, 1} for i = 1, 2 is the sensitivity status of a covariate with respect to the outcome i.
K1 = 1 ∧K2 = 0 K1 = 0 ∧K2 = 1 K1 = 1 ∧K2 = 1 K1 = 0 ∧K2 = 0
S1 = 1 ∧ S2 = 0 θ1, σ21 , ρ1 θ2, σ22 , ρ2 θ12, σ212, ρ12 η, ξ2, τ
S1 = 0 ∧ S2 = 1 ν1, ζ21 , κ1 ν2, ζ22 , κ2 ν12, ζ212, κ12 η, ξ2, τ
S1 = 1 ∧ S2 = 1 θ1, σ21 , ρ1 θ2, σ22 , ρ2 θ12, σ212, ρ12 η, ξ2, τ
S1 = 0 ∧ S2 = 0 ν1, ζ21 , κ1 ν2, ζ22 , κ2 ν12, ζ212, κ12 η, ξ2, τ
Supplementary Table 3. Cluster-wise rates of responses in each arm in the START trial.
Cluster 1 Cluster 2 Cluster 3 Cluster 4
control treatment control treatment control treatment control treatment
Mean offender rate 0.57 0.27 0.43 0.36 0.30 0.44 0.40 0.49
Mean substance use rate 0.49 0.23 0.41 0.41 0.42 0.36 0.45 0.43
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Supplementary Table 4. Covariates and coefficients for the CVRS2 method in the START trial. For each outcome, the
covariates are ordered according to their coefficients.
Offender status Substance use status
Covarite Coefficient Covariate Coefficient
YouthAdolescent 0.614 C_DAW_GenAnxT1 0.807
C_DAW_SepAnxT1 0.614 C_DAW_ADHDInattT1 0.591
RegisteredMainstreamT1 0.435 C_DAW_MajDepT1 0.525
OnsetCD 0.410 YouthAdolescent 0.504
C_DAW_ADHDCombT1 0.367 OnsetCD 0.355
C_DAW_SpePhobT1 0.340 C_DAW_SpePhobT1 0.314
YP_SDQ_CDT1 0.163 HLM_NVAP.P1 0.309
P_ALAB_CorPunT1 0.155 HLM_All.Offs.P1 0.261
YP_SDQ_HyperT1 0.145 C_DAW_ODT1 0.213
P_SDQ_HyperT1 0.132 HLM_VAP.P1 0.207
P_SDQ_EmotT1 0.129 YP_SDQ_HyperT1 0.126
YP_ALAB_PunishT1 0.116 C_DAW_CDT1 0.108
P_ALAB_MonT1 0.076 YP_SDQ_PeerRelT1 0.079
C_DAW_CDT1 0.076 YP_SDQ_CDT1 0.076
C_DAW_ODT1 0.071 YP_SDQ_EmotT1 0.076
P_SDQ_CDT1 0.071 P_SDQ_TotalImpactT1 0.068
YP_ALAB_MonitoringT1 0.050 C_DAW_ADHDCombT1 0.062
YP_SRD_Del_ExSib_VarT1 0.040 YP_SDQ_TotalImpactT1 0.056
P_CONN_ADHDTscoreT1 0.036 YP_SDQ_TotalDiffScoreT1 0.053
P_SDQ_TotalDiffScoreT1 0.029 P_SDQ_EmotT1 0.046
YP_ICU_TotalT1 0.028 P_SDQ_CDT1 0.040
IQ 0.026 P_ALAB_CorPunT1 0.031
YP_LEE_TotalT1 0.020 C_DAW_ADHDHypT1 0.028
P_ICU_TotalT1 0.019 YP_SRD_SubMis_VolT1 0.026
YP_SDQ_TotalDiffScoreT1 0.013 P_SDQ_PeerRelT1 0.025
YP_SRD_SubMis_VarT1 0.013 IQ 0.024
YP_SRD_Del_ExSib_VolT1 0.012 P_CONN_ADHDTscoreT1 0.021
YP_ABAS_TotalT1 0.012 P_ICU_TotalT1 0.020
YP_SMF_TotalT1 0.010 C_DAW_SepAnxT1 0.019
P_GHQ_TotalT1 0.004 YP_SMF_TotalT1 0.015
P_CONN_LEARLANGTscoreT1 0.002 YP_ALAB_PunishT1 0.015
Off_NOff 0.000 P_SDQ_TotalDiffScoreT1 0.012
HLM_CUST.P1 0.000 RegisteredMainstreamT1 0.012
C_DAW_SepPhobT1 0.000 P_SDQ_HyperT1 0.007
C_DAW_AgorT1 0.000 YP_LEE_TotalT1 0.006
C_DAW_OCDT1 0.000 YP_ABAS_TotalT1 0.003
C_DAW_AnxT1 0.000 Off_NOff 0.000
C_DAW_OtherDepT1 0.000 HLM_CUST.P1 0.000
C_DAW_ManiaT1 0.000 C_DAW_SepPhobT1 0.000
C_DAW_PanDisT1 0.000 C_DAW_AgorT1 0.000
C_DAW_UndiffAnxT1 0.000 C_DAW_OCDT1 0.000
C_DAW_OtherHypT1 0.000 C_DAW_AnxT1 0.000
C_DAW_OtherDistT1 0.000 C_DAW_OtherDepT1 0.000
C_DAW_SelectMutT1 0.000 C_DAW_ManiaT1 0.000
C_DAW_AttachDis_InhibT1 0.000 C_DAW_PanDisT1 0.000
C_DAW_AttachDis_DisinT1 0.000 C_DAW_UndiffAnxT1 0.000
C_DAW_AttachDis_OtherT1 0.000 C_DAW_OtherHypT1 0.000
C_DAW_PDDT1 0.000 C_DAW_OtherDistT1 0.000
C_DAW_EatDisT1 0.000 C_DAW_SelectMutT1 0.000
C_DAW_SteretypicT1 0.000 C_DAW_AttachDis_InhibT1 0.000
C_DAW_TicT1 0.000 C_DAW_AttachDis_DisinT1 0.000
C_DAW_PsychosisT1 0.000 C_DAW_AttachDis_OtherT1 0.000
C_DAW_OtherT1 0.000 C_DAW_PDDT1 0.000
YP_YouthMatScaleT1 -0.002 C_DAW_EatDisT1 0.000
YP_SRD_PeerIllSubT1 -0.006 C_DAW_SteretypicT1 0.000
RegisteredSpecialistEducT1 -0.006 C_DAW_TicT1 0.000
YP_SRD_SubMis_VolT1 -0.008 C_DAW_PsychosisT1 0.000
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YP_ALAB_DiscipT1 -0.010 C_DAW_OtherT1 0.000
P_LOEB_TotalT1 -0.014 YP_SRD_Del_ExSib_VarT1 0.000
P_FACE_FlexibilityDimensionT1 -0.016 P_LOEB_TotalT1 -0.003
P_FACE_CohesionDimensionT1 -0.019 YP_SRD_SubMis_VarT1 -0.003
P_ALAB_IncDisT1 -0.026 P_CONN_LEARLANGTscoreT1 -0.003
P_SDQ_TotalImpactT1 -0.029 P_ALAB_IncDisT1 -0.004
YP_SDQ_TotalImpactT1 -0.053 P_GHQ_TotalT1 -0.004
P_ALAB_PosParentT1 -0.055 YP_SRD_Del_ExSib_VolT1 -0.007
P_FACE_FSatT1 -0.059 YP_YouthMatScaleT1 -0.008
P_FACE_FCommT1 -0.065 YP_ICU_TotalT1 -0.013
P_SDQ_ProSocT1 -0.071 P_FACE_CohesionDimensionT1 -0.015
YP_SRD_PeerDelT1 -0.073 YP_ALAB_DiscipT1 -0.019
P_SDQ_PeerRelT1 -0.084 YPEducEmpT1 -0.023
YP_SDQ_EmotT1 -0.085 P_FACE_FlexibilityDimensionT1 -0.024
YP_SDQ_PeerRelT1 -0.090 YP_ALAB_MonitoringT1 -0.034
C_DAW_PTSDT1 -0.093 P_FACE_FSatT1 -0.036
YP_ALAB_PosParentT1 -0.104 P_FACE_FCommT1 -0.057
Age -0.108 YP_ALAB_PosParentT1 -0.067
YP_ALAB_ParInvT1 -0.113 P_ALAB_MonT1 -0.068
YP_SDQ_ProSocT1 -0.139 YP_SDQ_ProSocT1 -0.074
P_ALAB_ParInvT1 -0.146 YP_SRD_PeerIllSubT1 -0.077
HLM_OthBr.P1 -0.204 P_ALAB_ParInvT1 -0.081
C_DAW_GenAnxT1 -0.227 YP_SRD_PeerDelT1 -0.093
C_DAW_MajDepT1 -0.240 gender -0.096
C_DAW_ADHDHypT1 -0.245 YP_ALAB_ParInvT1 -0.100
gender -0.288 HLM_OthBr.P1 -0.117
C_DAW_ADHDInattT1 -0.448 Age -0.123
HLM_All.Offs.P1 -0.668 P_ALAB_PosParentT1 -0.134
YPEducEmpT1 -0.720 P_SDQ_ProSocT1 -0.210
HLM_VAP.P1 -0.992 RegisteredSpecialistEducT1 -0.268
HLM_NVAP.P1 -1.549 C_DAW_PTSDT1 -0.609
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Supplementary Table 5. Covariates and coefficients for the marginal CVRS method in the START trial. For each
outcome, the covariates are ordered according to their coefficients.
Offender status Substance use status
Covariate Coefficient Covarite Coefficient
C_DAW_SepPhobT1 7.461 C_DAW_PDDT1 11.345
C_DAW_OtherT1 7.192 C_DAW_PanDisT1 7.144
C_DAW_PanDisT1 7.116 HLM_CUST.P1 6.710
C_DAW_PDDT1 6.799 C_DAW_GenAnxT1 1.703
C_DAW_TicT1 4.830 C_DAW_ADHDInattT1 0.585
C_DAW_SepAnxT1 2.145 C_DAW_MajDepT1 0.507
YouthAdolescent 0.616 YouthAdolescent 0.505
HLM_CUST.P1 0.502 HLM_All.Offs.P1 0.360
RegisteredMainstreamT1 0.432 OnsetCD 0.354
C_DAW_SpePhobT1 0.430 HLM_NVAP.P1 0.315
OnsetCD 0.409 C_DAW_SpePhobT1 0.284
C_DAW_ADHDCombT1 0.367 HLM_VAP.P1 0.201
YP_SDQ_CDT1 0.162 C_DAW_ODT1 0.185
P_ALAB_CorPunT1 0.156 C_DAW_TicT1 0.130
YP_SDQ_HyperT1 0.145 C_DAW_OtherT1 0.128
P_SDQ_HyperT1 0.132 YP_SDQ_HyperT1 0.126
P_SDQ_EmotT1 0.128 C_DAW_CDT1 0.109
YP_ALAB_PunishT1 0.116 C_DAW_ADHDHypT1 0.098
C_DAW_ODT1 0.078 YP_SDQ_PeerRelT1 0.078
P_ALAB_MonT1 0.075 YP_SDQ_EmotT1 0.076
C_DAW_CDT1 0.073 YP_SDQ_CDT1 0.074
P_SDQ_CDT1 0.071 P_SDQ_TotalImpactT1 0.068
YP_ALAB_MonitoringT1 0.050 C_DAW_ADHDCombT1 0.062
YP_SRD_Del_ExSib_VarT1 0.040 YP_SDQ_TotalImpactT1 0.057
P_CONN_ADHDTscoreT1 0.036 YP_SDQ_TotalDiffScoreT1 0.052
P_SDQ_TotalDiffScoreT1 0.029 P_SDQ_EmotT1 0.047
YP_ICU_TotalT1 0.028 P_SDQ_CDT1 0.039
IQ 0.027 P_ALAB_CorPunT1 0.032
YP_LEE_TotalT1 0.020 P_SDQ_PeerRelT1 0.025
P_ICU_TotalT1 0.019 IQ 0.024
YP_SDQ_TotalDiffScoreT1 0.013 P_CONN_ADHDTscoreT1 0.021
YP_SRD_SubMis_VarT1 0.013 P_ICU_TotalT1 0.019
YP_SRD_Del_ExSib_VolT1 0.013 YP_SMF_TotalT1 0.015
YP_ABAS_TotalT1 0.012 YP_ALAB_PunishT1 0.014
YP_SMF_TotalT1 0.009 P_SDQ_TotalDiffScoreT1 0.012
P_GHQ_TotalT1 0.004 RegisteredMainstreamT1 0.010
P_CONN_LEARLANGTscoreT1 0.002 P_SDQ_HyperT1 0.008
C_DAW_AgorT1 0.000 YP_LEE_TotalT1 0.006
C_DAW_AnxT1 0.000 YP_SRD_SubMis_VolT1 0.005
C_DAW_OtherDepT1 0.000 YP_ABAS_TotalT1 0.003
C_DAW_ManiaT1 0.000 C_DAW_AgorT1 0.000
C_DAW_UndiffAnxT1 0.000 C_DAW_AnxT1 0.000
C_DAW_OtherHypT1 0.000 C_DAW_OtherDepT1 0.000
C_DAW_OtherDistT1 0.000 C_DAW_ManiaT1 0.000
C_DAW_SelectMutT1 0.000 C_DAW_UndiffAnxT1 0.000
C_DAW_AttachDis_InhibT1 0.000 C_DAW_OtherHypT1 0.000
C_DAW_AttachDis_DisinT1 0.000 C_DAW_OtherDistT1 0.000
C_DAW_AttachDis_OtherT1 0.000 C_DAW_SelectMutT1 0.000
C_DAW_SteretypicT1 0.000 C_DAW_AttachDis_InhibT1 0.000
C_DAW_PsychosisT1 0.000 C_DAW_AttachDis_DisinT1 0.000
YP_YouthMatScaleT1 -0.002 C_DAW_AttachDis_OtherT1 0.000
YP_SRD_PeerIllSubT1 -0.005 C_DAW_SteretypicT1 0.000
RegisteredSpecialistEducT1 -0.006 C_DAW_PsychosisT1 0.000
YP_SRD_SubMis_VolT1 -0.009 P_LOEB_TotalT1 -0.003
YP_ALAB_DiscipT1 -0.010 P_CONN_LEARLANGTscoreT1 -0.003
P_LOEB_TotalT1 -0.014 YP_SRD_Del_ExSib_VarT1 -0.003
P_FACE_FlexibilityDimensionT1 -0.016 P_GHQ_TotalT1 -0.004
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P_FACE_CohesionDimensionT1 -0.019 P_ALAB_IncDisT1 -0.004
P_ALAB_IncDisT1 -0.027 YP_SRD_Del_ExSib_VolT1 -0.007
P_SDQ_TotalImpactT1 -0.029 YP_YouthMatScaleT1 -0.008
YP_SDQ_TotalImpactT1 -0.053 YP_ICU_TotalT1 -0.013
P_ALAB_PosParentT1 -0.055 P_FACE_CohesionDimensionT1 -0.015
P_FACE_FSatT1 -0.058 YP_ALAB_DiscipT1 -0.018
P_FACE_FCommT1 -0.064 P_FACE_FlexibilityDimensionT1 -0.024
P_SDQ_ProSocT1 -0.072 YP_ALAB_MonitoringT1 -0.033
YP_SRD_PeerDelT1 -0.073 P_FACE_FSatT1 -0.036
P_SDQ_PeerRelT1 -0.081 YP_SRD_SubMis_VarT1 -0.037
YP_SDQ_EmotT1 -0.083 P_FACE_FCommT1 -0.056
YP_SDQ_PeerRelT1 -0.088 YP_ALAB_PosParentT1 -0.067
C_DAW_PTSDT1 -0.092 P_ALAB_MonT1 -0.069
YP_ALAB_PosParentT1 -0.104 YP_SDQ_ProSocT1 -0.074
Age -0.108 YP_SRD_PeerIllSubT1 -0.077
YP_ALAB_ParInvT1 -0.113 P_ALAB_ParInvT1 -0.082
YP_SDQ_ProSocT1 -0.138 YP_SRD_PeerDelT1 -0.094
P_ALAB_ParInvT1 -0.147 gender -0.095
C_DAW_MajDepT1 -0.237 YP_ALAB_ParInvT1 -0.099
Off_NOff -0.241 Age -0.126
gender -0.289 P_ALAB_PosParentT1 -0.134
C_DAW_ADHDInattT1 -0.440 P_SDQ_ProSocT1 -0.208
C_DAW_GenAnxT1 -0.954 RegisteredSpecialistEducT1 -0.264
C_DAW_ADHDHypT1 -0.973 HLM_OthBr.P1 -0.289
HLM_VAP.P1 -0.982 Off_NOff -0.300
HLM_All.Offs.P1 -1.025 YPEducEmpT1 -0.475
HLM_NVAP.P1 -1.723 C_DAW_SepPhobT1 -0.530
HLM_OthBr.P1 -2.087 C_DAW_PTSDT1 -0.610
C_DAW_OCDT1 -6.210 C_DAW_SepAnxT1 -0.687
YPEducEmpT1 -12.128 C_DAW_OCDT1 -5.317
C_DAW_EatDisT1 -14.808 C_DAW_EatDisT1 -14.682
Note: The covariates that have the largest absolute values of the coefficients for the marginal
CVRS, have coefficients equal to zero for the CVRS2 (for example, the C_DAW_EatDisT1
covariate which is a diagnosis of eating disorder). This is because the single-covariate regression
with the vglm R function which is used in the CVRS2 method returns warnings "fitted values close
to 0 or 1" and "some quantities such as z, residuals, SEs may be inaccurate due to convergence at
a half-step" meaning that the coefficients are not reliable and therefore we set them to zero. (The
warnings are most probably caused by a very small inter-subjects variability of the values of these
covariates). In the marginal CVRS however, the glm R function computes the coefficients without
a warning. For example, the C_DAW_EatDisT1 covariate has value “0" for 459 participants, value
“1" for one participant and value “4" for one participant. It has the largest absolute value of the
coefficient in the marginal CVRS (the coefficients are −14.808 and −14.682 with respect to the
offender status and the substance use status, respectively), while for the CVRS2, the coefficients
have been assigned a value of zero due to the warnings.
1 Simulation steps
1. Assign sensitivity status to each subject w. r. t. response 1 using Bernoulli distribution.
2. Assign sensitivity status to each subject w. r. t. response 2 using Bernoulli distribution.
3. Assign sensitivity status to each covariate w. r. t. response 1.
4. Assign sensitivity status to each covariate w. r. t. response 2.
5. Assign treatment arm status to each subject (equal randomisation).
6. Simulate the values for the gene expressions, xij , from the multivariate normal distribution conditional of the
sensitivity status of the subjects and of the covariates, as specified in Supplementary Table 2.
7. For each subject, compute linear predictors ωi for the responses i = 1, 2 using equations (2.3) and (2.4). The
required parameters for computing ωi are obtained as follows:
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7a. Set α(i)1 , . . . , α
(i)
Ki
= 0 and λ(i) = 0 for i = 1, 2, where k = 1, . . . ,Ki are the indices of the covariates that
are sensitive to response i.
7b. Compute µ(i) so that it corresponds to a 25% response rate on the control arm, i.e. µ(i) = log(0.25/0.75).
7c. Compute γ(i)1 , . . . , γ
(i)
Ki
so that they correspond to the desirable response rate in the sensitive group on
treatment, RRi, i.e.
γ
(i)
k =
log
(
RRi
1−RRi
)
− µ(i)
Kiθi
.
8. Compute probability of response as pi = exp(ωi)/(1 + exp(ωi)).
9. Assign response i to each subject using Bernoulli distribution with parameter pi.
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